{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:10:09Z","timestamp":1790831409811,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ejso.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T13:34:30Z","timestamp":1480944870000},"page":"1161-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"43","author":[{"given":"P.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.-M.","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-F.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.-S.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-T.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2016.11.011_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21320","article-title":"Breast cancer statistics, 2015: convergence of incidence rates between black and white women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2016.11.011_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2016.11.011_bib3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<698::AID-CNCR10>3.0.CO;2-N","article-title":"Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause","volume":"83","author":"Pujol","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib4","series-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: breast cancer version 1","year":"2016"},{"key":"10.1016\/j.ejso.2016.11.011_bib5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2016.11.011_bib6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2147\/OTT.S86817","article-title":"Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials","volume":"8","author":"Yan","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejso.2016.11.011_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2016.11.011_bib8","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2011.36.4950","article-title":"American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer","volume":"29","author":"Griggs","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative G","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2016.11.011_bib10","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2016.11.011_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2016.11.011_bib12","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejso.2016.11.011_bib13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2016.11.011_bib14","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2016.11.011_bib15","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(00)04934-5","article-title":"Bringing it all together: Lancet-Cochrane collaborate on systematic reviews","volume":"357","author":"Clarke","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2016.11.011_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1503\/cmaj.1031920","article-title":"Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results","volume":"172","author":"Hatala","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.ejso.2016.11.011_bib17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/1097-0142(19880601)61:11<2168::AID-CNCR2820611106>3.0.CO;2-F","article-title":"A\u00a0randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors","volume":"61","author":"Nomura","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2016.11.011_bib19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.1985.3.8.1059","article-title":"Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer","volume":"3","author":"Goldhirsch","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.1986.4.9.1326","article-title":"A\u00a0randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast-cancer","volume":"4","author":"Buchanan","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.1986.4.2.178","article-title":"Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer","volume":"4","author":"Ingle","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1987.5.6.881","article-title":"Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study","volume":"5","author":"Falkson","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/oxfordjournals.annonc.a057718","article-title":"Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients","volume":"1","author":"Goldhirsch","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib24","first-page":"1293","article-title":"Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial","volume":"341","author":"Bartlett","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2016.11.011_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1996.14.1.46","article-title":"Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study","volume":"14","author":"Rivkin","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/A:1005895813401","article-title":"A\u00a0randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1","volume":"44","author":"Sawka","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2016.11.011_bib27","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2000.18.14.2718","volume":"18","author":"Boccardo","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2016.11.011_bib29","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2002.09.112","volume":"20","author":"Jakesz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib30","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/ejso.2002.1280","article-title":"Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study","volume":"28","author":"S\u00f6reide","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib32","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"International Breast Cancer Study G","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2016.11.011_bib33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/annonc\/mdi085","article-title":"Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"16","author":"Arriagada","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib34","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1200\/JCO.2005.05.551","article-title":"Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)","volume":"23","author":"Davidson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bjc.6602355","article-title":"A\u00a0randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer","volume":"92","author":"De Placido","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib36","first-page":"2071","article-title":"[Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B]","volume":"32","author":"Mitsuyama","year":"2005","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ejso.2016.11.011_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2005.12.013","article-title":"Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study","volume":"42","author":"Baum","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib38","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1200\/JCO.2005.05.1235","article-title":"Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer","volume":"24","author":"Ejlertsen","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdl107","article-title":"Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial","volume":"17","author":"Roche","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib40","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.ejca.2006.04.006","article-title":"CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)","volume":"42","author":"von Minckwitz","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib41","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djk109","article-title":"Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial","volume":"99","author":"Adjuvant Breast Cancer Trials Collaborative G","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2016.11.011_bib42","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ejca.2007.08.012","article-title":"A\u00a0randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer \u2013 GABG-IV B-93","volume":"43","author":"Kaufmann","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.11.011_bib43","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib44","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.11.011_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(96)05023-4","article-title":"Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group","volume":"348","author":"Clarke","year":"1996","journal-title":"Lancet"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316310058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316310058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:34:13Z","timestamp":1568604853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798316310058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0748798316310058"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.11.011","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}